MedTrace Logo

Denosumab for the Treatment of Adult LCH

NCT03270020 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-01-15

No results posted yet for this study

Summary

This study is aiming to evaluate the efficacy of denosumab among adult patients suffering from Langerhans Cell Histiocytosis (LCH).

Conditions

  • Langerhans Cell Histiocytosis

Interventions

DRUG

Denosumab 70 MG/ML [Xgeva]

As already described in arm description

Sponsors & Collaborators

  • Hellenic Society for the Study of Bone Metabolism

    lead OTHER

Principal Investigators

  • Polyzois Makras, MD, PhD · Dpt of Endocrinology & Diabetes, 251 Hellenic AirForce & VA General Hospital, Athens, Greece

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-07
Primary Completion
2022-06-22
Completion
2025-01-14

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03270020 on ClinicalTrials.gov